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140Disturbances in acid-base balance, such as acidosis and alkalosis, have potential to
alter the pharmacologic and toxicologic outcomes of statin therapy. Statins are
commonly prescribed for elderly patients who have multiple comorbidities such as
diabetes mellitus, cardiovascular, and renal diseases. These patients are at risk of
developing acid-base imbalance. In the present study, the effect of disturbances
in acid-base balance on the interconversion of simvastatin and pravastatin between
lactone and hydroxy acid forms have been investigated in physiological buffers,
human plasma, and cell culture medium over pH ranging from 6.8–7.8. The effects
of such interconversion on cellular uptake and myotoxicity of statins were assessed
in vitro using C2C12 skeletal muscle cells under conditions relevant to acidosis,
alkalosis, and physiological pH. Results indicate that the conversion of the lactone
forms of simvastatin and pravastatin to the corresponding hydroxy acid is strongly
pH dependent. At physiological and alkaline pH, substantial proportions of simva-
statin lactone (SVL; 87% and 99%, respectively) and pravastatin lactone (PVL;
98% and 99%, respectively) were converted to the active hydroxy acid forms after
24 hours of incubation at 37C. At acidic pH, conversion occurs to a lower extent,
resulting in greater proportion of statin remaining in the more lipophilic lactone
form. However, pH alteration did not influence the conversion of the hydroxy acid
forms of simvastatin and pravastatin to the corresponding lactones. Furthermore,
acidosis has been shown to hinder the metabolism of the lactone form of statins by
inhibiting hepatic microsomal enzyme activities. Lipophilic SVL was found to be
more cytotoxic to undifferentiated and differentiated skeletal muscle cells
compared with more hydrophilic simvastatin hydroxy acid, PVL, and pravastatin
hydroxyacid. Enhancedcytotoxicity of statinswas observed under acidic conditions
and is attributed to increased cellular uptake of themore lipophilic lactone or union-
ized hydroxy acid form. Consequently, our results suggest that comorbidities
associated with acid-base imbalance can play a substantial role in the develop-
ment and potentiation of statin-induced myotoxicity. (Translational Research
2016;174:140–160)Abbreviations: cDNA ¼ complementary DNA; Ct ¼ cycle threshold; DMEM ¼ Dulbecco’s
modified eagle medium; Gapdh ¼ glyceraldehyde-3-phosphate dehydrogenase; Hprt ¼hemistry and Structural Biology,
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Volume 174 Taha et al 141hypoxanthine phosphoribosyl transferase; HQC¼ high concentration quality control; IS ¼ inter-
nal standard; LDH ¼ lactate dehydrogenase; LLOQ ¼ lower limit of quantification; LOV-A ¼
lovastatin hydroxy acid; LOV-L ¼ lovastatin lactone; LQC ¼ low concentration quality control;
MHC ¼ myosin heavy chain; MQC ¼ medium concentration quality control; mRNA ¼
messenger RNA; MRP ¼ multiresistant protein; MTT ¼ thiazolyl blue tetrazolium bromide; NA ¼
nonapplicable; OATP ¼ organic anionic transporting polypeptide; PBS ¼ phosphate buffer
saline; PVA ¼ pravastatin hydroxy acid; PVL ¼ pravastatin lactone; RSD ¼ relative standard
deviation; RE ¼ relative error; Rps12 ¼ ribosomal protein S12; SVA ¼ simvastatin hydroxy acid;
SVL ¼ simvastatin lactone; Tbp ¼ TATA box-binding proteinENTARY
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Statins are cholesterol-lowering drugs commonly
used to reduce morbidity and mortality associated with
atherosclerotic cardiovascular diseases.1 Recent data
from the National Center for Health Statistics reveals
that 27.9% of American men and women of 40 years
and older are taking statins.2 In recent years, a significant
increase in the number of statin prescriptions has been
reported by the British Heart Foundation with more
than 7 million people currently taking either prescribedor over the counter statins in the UK.3 According to the
American College of Cardiology and American
Heart Association guidelines4,5 for prediction of
cardiovascular risk factors, more than 1 billion people
worldwide are now estimated to use statins.6
Statins are generally well tolerated, but muscular
adverse effects considerably influence drug tolerability
and patient adherence especially with long-term use.1
The exact mechanism by which these drugs induce their
myotoxic effects is not fully understood. Simvastatin, a
highly lipophilic statin, is the most commonly
prescribed cholesterol-lowering medication, and 42%
of American adults who are using cholesterol-
lowering drugs are prescribed this drug.2 It has been
postulated that lipophilic statins are more myotoxic
than hydrophilic ones, most probably because of their
ability to penetrate skeletal muscle tissues and alter
membrane structure.7-9 Nonetheless, the ability of
lipophilic statins to penetrate hepatic cells makes
them more potent in reducing elevated cholesterol
levels.9 This property might explain their wider use
comparing to hydrophilic statins.
Several risk factors have been suggested to predispose
patients to statin-associated myotoxicity including
advanced age, high dose, female gender, drug interac-
tions, genetic variability of drug metabolizing enzymes
and transporters, lipophilicity of statins, and coincident
morbidities.10 Statins are administered either as lactone
or hydroxy acid forms. The lactone form is pharmaco-
logically inactive, whereas the hydroxy acid is the active
form that lowers plasma cholesterol levels.8 Substantial
differences exist between these forms in termof their lip-
ophilicity. The lactone form is highly lipophilic, whereas
hydroxy acid has poor lipid solubility.9,11 It has been
reported that lactone form is more myotoxic than the
active acid form owing to its lipophilicity.8,12,13
In vivo, interconversion between both forms is
mediated by enzymatic as well as pH-dependent chem-
ical reaction in plasma, liver, and other tissues.14-17
Therefore, acid-base imbalance can potentially alter
the lipophilicity of statins by affecting their interconver-
sion between lactone and hydroxy acid forms. The
higher lipophilicity of statins in the lactone form can
potentially facilitate their penetration into muscle cells
Fig 1. Schematic diagram for the possible mechanisms of statin interconversion between lactone and hydroxy acid
forms and potential effect onmembrane permeability. The interconversion between the 2 forms ismediated by pH and
enzyme-dependent process. The higher lipophilicity of statins in the lactone form can potentially facilitate their
penetration into muscle cells and consequently induce high local drug concentrations within skeletal muscle tissues.
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within skeletal muscle tissues (Fig 1).
Disturbance in acid-base imbalance is quite common
among statin users. Many patients receiving statins are
elderly and have multiple co-morbidities such as
diabetesmellitus, cardiovascular and renal diseases, or us-
ing diuretics. These conditions have been reported to lead
to development of acidosis or alkalosis.18 Normally, the
pH of blood plasma is maintained within narrow limits
of 7.35–7.45. Most often, acidosis or alkalosis develops
when there is a mild disturbance in blood plasma pH
outside this range.19 Nevertheless, extreme disturbances
inacid-basebalancewith bloodpHof less than7orgreater
than 7.65have been reported in intensive care units among
patients with long-term diuretic abuse,20 diabetic
ketoacidosis,21,22 lactic acidosis,23,24 hypovolemic
shock,25 and ethylene glycol intoxication.26-28
Although acid-base imbalance has been proposed to be
a possible risk factor for statin-induced myotoxicity, the
effect of disturbances in acid-base balance on the devel-
opment and potentiation of statin-related myotoxicity
has received only limited investigation.29-32 Limited
numbers of in vitro studies have been done to evaluate
the myotoxicity pattern of statins at pH relevant toacidosis and alkalosis using number of skeletal muscle
cell lines. Results from these studies indicate enhanced
cytotoxicity of statins under acidic conditions.
However, the relationship between the pH-dependent
interconversion of statins and their myotoxicity has not
been addressed as a possible cause in these studies.29-32
Therefore, the overall aim of this work was to eluci-
date the role of acid-base imbalance in statin-induced
muscle toxicity. Simvastatin was selected as a model
lipophilic statin in this study because of its high lipophi-
licity, wide clinical use, and high incidence of reported
simvastatin-associated muscle toxicity.2,33 Pravastatin
was selected as a model hydrophilic statin with
expected lower myotoxicity. The objectives included
elucidation of the effect of disturbances in acid-base bal-
ance on the interconversion of statins between lactone
and hydroxy acid forms, assessment of statin uptake
by muscle cells under conditions relevant to acidosis,
alkalosis and physiological pH, and evaluation of the
role of statin interconversion in skeletal muscle toxicity.
MATERIALS AND METHODS
Materials. Simvastatin lactone (SVL, 99.3%) and
pravastatin hydroxy acid sodium (PVA, 99.4%) were
Translational Research
Volume 174 Taha et al 143purchased from Kemprotec Ltd (Lancashire, UK),
simvastatin hydroxy acid ammonium salt (SVA, 98.0%)
and pravastatin lactone (PVL, 98%) from Toronto
ResearchChemicals Inc (Toronto,Canada), lovastatin hy-
droxy acid sodium (LOV-A, 98.0%) and griseofulvin
(97.0%) from Alfa-Aesar (Lancashire, UK), lovastatin
lactone (LOV-L, 97.0%) from Cayman (Leicestershire,
UK), and 4,4-dichlorodiphenyltrichloroethane (98.0%)
from Sigma–Aldrich (Dorset, UK). Dulbecco’s
Modified Eagle Medium (42430025-Dulbecco’s
modified eagle medium [DMEM], high glucose, 4-2-
hydroxyethyl-1-piperazineethanesulfonic acid without
sodium pyruvate) was purchased from Invitrogen-Life
Technologies (Paisley, UK). Thiazolyl blue tetrazolium
bromide (MTT) was purchased from Alfa-Aesar
(Lancashire, UK). Total RNA isolation kit (NucleoSpin
RNA II) was supplied by Macherey-Nagel, GmbH &
Co KG (D€uren, Germany). GoTaq qPCR Master Mix
was obtained from Promega (Southampton, UK).
SuperScript IV Reverse Transcriptase was purchased
from Invitrogen-Life Technologies (Paisley, UK).
Random Hexamers (50 mM), dNTP mix (10 mM each),
and Pierce lactate dehydrogenase (LDH) Cytotoxicity
Assay kit were purchased from Thermo Fisher
Scientific (Loughborough, UK). Pooled human liver
microsomes of 20 mg/mL were purchased from
Invitrogen-Life Technologies (Paisley, UK). MgCl2,
KH2PO4, K2HPO4, and reduced nicotinamide adenine
dinucleotide phosphate (NADPH) were purchased from
Sigma–Aldrich (Gillingham, UK). All reagents used
were of high performance liquid chromatography
(HPLC) grade. Ultrapure water was obtained by passing
distilled water through ELGAwater purification system
before use.
The pH modification of human plasma, DMEM culture
medium, andphosphate buffer saline. Sodium phosphate
buffer has been used to adjust the pH of human plasma
as previously described with some modification.34 The
pH adjustment was done in 3 steps. In the first step, a
fixed volume of human plasma samples was adjusted
to the target pH (6.8–7.8) by adding appropriate
volumes of either mono or dibasic sodium phosphate
solution. After that, series of sodium phosphate buffer
solutions of predefined pH were prepared at a
concentration of 1 mol/L by mixing appropriate
volumes of mono and dibasic sodium phosphates
solution. Finally, one volume of phosphate buffer
solutions (of defined pH) was mixed with 9 volumes
of plasma samples, the pH of the resulting mixture
was measured by Mettler Toledo T50 pH titrator, and
minor adjustments were made as appropriate.
The pH of DMEM culture medium was adjusted to
the target values (6.8–7.8) by adding an appropriate
volume of either 1.0 N HCl or NaOH to a mediumcontaining 20 mmol/L 4-2-hydroxyethyl-1-
piperazineethanesulfonic acid (HEPES) buffer. The
pH was measured at incubation temperature (37C) by
Mettler Toledo T50 pH titrator. Before the experiments,
the medium was kept in an incubator for 24 hours under
cell culture conditions (37C and 5% CO2) to allow the
desired pH ranges to equilibrate. After equilibration,
minor adjustment in pH was occasionally required to
reach the desired final pH.35 Maintaining medium under
constant CO2 environment of 5% stabilizes the pH
through CO2-HCO3
2 equilibrium.36 The pH of
phosphate buffer saline (PBS) was adjusted to the target
values (6.8–7.8) in the same way without the need for
equilibration.
Interconversion of statins in human plasma, PBS, and
DMEM culture medium. The interconversion of the
lactone and hydroxy acid forms of simvastatin and
pravastatin was investigated by incubating tested
compounds with human plasma, PBS, and DMEM
culture medium of defined pH values at 37C for a
predetermined period of time. Four different concentra-
tions were examined for each statin (12.5, 25, 50, and
100 mmol/L for SVL and SVA and 25, 50, 100, and
200 mmol/L for PVL and PVA). Human plasma and
PBS samples were incubated in C25 classic incubator
shaker (New Brunswick Scientific). For DMEM
samples, CO2 supply was maintained at 5% throughout
experiment in a tissue culture incubator. The pH of
different matrices was adjusted to simulate physiolog-
ical pH, acidosis, and alkalosis as described previously.
After incubation, the interconversion reaction was
stopped at predetermined time points by adding 50 mL
of ice-cold ammonium acetate buffer (100 mmol/L,
pH 4.5) to 100 mL of tested samples.14 Six replicates
were tested at each pH level, and the concentrations of
parent and corresponding forms were measured by
fully validated HPLC analytical methods.
Metabolicmicrosomal stability. Microsomal metabolic
stability assay was conducted using human liver
microsomes. The reaction mixture consisted of
MgCl2, human liver microsomes, NADPH, and SVL at
final concentrations of 10 mmol/L, 0.5 mg protein/mL,
1 mmol/L, and 1 mmol/L, respectively, in 84.7 mmol/L
potassium phosphate buffer. The buffer was prepared at
3 different pH levels of 6.8, 7.4, and 7.8 (simulating
acidosis, physiological pH, and alkalosis, respectively).
The reactionmixturewas preincubated at 37C in awater
bath for 3 minutes before the assay. The reaction was
initiated by the addition of NADPH to themixture. Sam-
ples of 100mLvolumewerewithdrawn from the reaction
mixture at 0.25, 5, 10, 20, 30, and 40 minutes and trans-
ferred into new tubes containing 1 mL of acetonitrile
(ACN) to terminate the reaction.Vortexmixingof30 sec-
onds was applied to each sample, and then, the samples
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chromatography-tandem mass spectrometry (LC
MS/MS) analysis. Half-life (t1/2) of SVL was
calculated using the following equation:
t1=252
0:693
k
(Eq. 1)
where k is the slope from the plot of natural log
percentage of SVL versus incubation time. The
experiment was performed in triplicates.
C2C12 growth and differentiation. C2C12 mouse
myoblast cells were cultured in a humidified environment
of 5% CO2 at 37
C. Cells were maintained subconfluent
(70%–80%) by growing in DMEM medium supple-
mented with 10% fetal bovine serum, 1% L-glutamine,
and 1% penicillin-streptomycin antibiotic mixture.
Myogenic differentiation was induced by growing the
cells in differentiation medium containing 2% horse
serum. The cells were cultured over a period of
4–6 days to allow complete differentiation, and the
medium was replaced every 24 hours.37
To verify the differentiation of C2C12, the expression
of 2 markers of myogenic differentiation (myogenin and
myosin heavy chain [MHC]) were assessed by real-time
reverse transcriptase quantitative polymerase chain
reaction (qPCR) at different stage of cells differentia-
tion. C2C12 was cultured on a 6-well plate at a density
of 2 3 105/mL. The cells were allowed to attach to the
well surface by incubation at 37C and 5% CO2. Differ-
entiation was induced on 80% confluence by switching
the cells to differentiation medium. On differentiation,
the medium was aspirated from the wells, and the cells
were harvested. Total RNA was extracted from
undifferentiated and differentiated cells at different
differentiation stages (day 1, 3, 5, 7, and 9) using
NucleoSpin RNA II extraction kit (the manufacturer’s
protocol was followed). The extracted RNAwas reverse
transcribed into complementary DNA (cDNA) using
random hexamer primers, dNTP mix (10 mM each),
and SuperScript VI (reverse transcriptase purified
from Escherichia. coli), and the resultant cDNA was
used as a template for polymerase chain reaction
(PCR) amplification.
The expression of differentiation marker genes
(myogenin and MHC) and 4 reference genes (TATA
box-binding protein [Tbp], glyceraldehyde-3-phosphate
dehydrogenase [Gapdh], hypoxanthine-guanine phos-
phoribosyltransferase [Hprt], and ribosomal protein
S12 [Rps12]) was assessed by real-time qPCR using
GoTaq qPCRMasterMix (Promega, UK) and previously
published primer sets.38 The primers used for the qPCR
were synthesized by Sigma–Aldrich Biotechnology,
UK (sequences are listed in Supplementary Table I).DNA amplification was carried out using Rotor-Gene
Q, (Qiagen thermal cycler). The PCR thermocycling
program consisted of an initial denaturation step at
95C for 10 minutes, followed by 45 cycles of 30 sec-
onds at 95C, 30 seconds at the optimal annealing tem-
perature of 55C, and 30 seconds at 72C for extension.
To confirm the amplification specificity, PCR products
were subjected to melting curve analysis. A standard
curve was constructed for each sample and was derived
from 10-fold serial dilution of cDNA template.
The levels of gene expressions in each sample over
the days of differentiation were calculated relative to
their expression in undifferentiated cells. Data were
normalized relative to the expression of Tbp gene (a
reference gene with minimal fluctuation in expression
over the periods of cell differentiation). All samples
were run in triplicate, and the mean value was used
for subsequent analysis. The DDcycle threshold (Ct)
value for each gene was determined by calculating the
difference between the Ct value of the target gene and
the Ct value of the reference gene. The normalized level
of the gene expression in each samplewas calculated us-
ing the formula 22DDCt, and the results were expressed
as fold changes in gene expression from the baseline
level observed with undifferentiated C2C12 myoblast
cells. Three reference genes (Gapdh, Hprt, and Rps12)
were used for validation of gene expression. The size
and the integrity of the amplicon in each sample was
assessed by running the qPCR products on 1.2% agarose
gel after staining with SYBR safe (Invitrogen-Life
Technologies, UK), and the bands were visualized
under UV light.
Cellular uptake of statins in response to altered medium
pH. C2C12 cells were cultured in 10 cm dishes at a den-
sity of 2 3 105/mL. Cells were allowed to attach for
24 hours or to differentiate for 4 days by switching to
differentiation medium containing 2% horse serum.
Before starting the uptake study, the medium was
removed and replaced by a fresh medium of modified
pH (relevant to physiological pH, acidosis, and
alkalosis) and the cells were allowed to equilibrate for
10 minutes. The uptake study was initiated by adding
SVL, SVA, PVL, or PVA to medium at a concentration
of 1 mmol/L. Cells were incubated for a predetermined
period of time at 37C under CO2 environment of 5%.
Statins uptake was terminated by suctioning off the
DMEM containing the tested drug, and the cells were
washed twice with ice-cold PBS (pH 7.4). Cells were
harvested by trypsinization and resuspended in
200 mL PBS (pH 7.4). Five replicates were tested at
each pH level and the intracellular concentration of
both the lactone and the corresponding hydroxy acid
forms of simvastatin and pravastatin were determined
in 100 mL of cell suspension using fully validated LC
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in the remaining cell suspension after pelleting and
lysing the cells with radio-immunoprecipitation issay
(RIPA) lysis buffer (150 mmol/L NaCl, 50 mmol/L
Tris-HCl [pH 8.0], 0.5% Nonidet P-40 [NP-40],
supplemented with proteinase inhibitor and
phosphatase inhibitor), using Bradford protein assay
and bovine serum albumin as a standard.39
Analytical procedures. HPLC analysis. Fully validated
HPLC-UVmethods were used to determine the concen-
trations of the lactone and the corresponding hydroxy
acid forms of simvastatin and pravastatin after intercon-
version studies in human plasma, PBS, and DMEM
culture medium of different pH. Samples for HPLC
analysis were prepared by protein precipitation
followed by liquid-liquid extraction. A 100 mL of
human plasma or DMEM samples were pipetted into
1.5 mL Eppendorf tubes, and 50 mL of ammonium ace-
tate buffer (100 mmol/L, pH 4.5) along with 10 mL of
internal standard solution (4,4-dichlorodiphenyltrich-
loroethane [DDT] or griseofulvin 100 mg/mL for simva-
statin and pravastatin containing samples, respectively)
was added, and samples were vortex mixed for 30 sec-
onds. Proteins were precipitated by the addition of
300 mL of chilled ACN, and samples were vortex mixed
for 1 minute and then centrifuged at 900g for 10 minutes
at 4C. After centrifugation, the ACN layer was trans-
ferred into new glass test tubes, and 3 mL of methyl
tert-butyl ether were added to each sample, vortex
mixed for 10 minutes, and centrifuged at 1,615g for
10 minutes at 4C. Finally, the upper organic layers
were separated using glass Pasteur pipette, transferred
into new glass tubes, and the contents of the tubes
were evaporated to dryness using Techne Sample
Concentrator (Bibby Scientific Ltd, UK). The dry
residues were reconstituted with 100 mL of the mobile
phase, vortex mixed, and placed into appropriate
HPLC vials. Samples from PBS were extracted in the
same way with one exception that the protein
precipitation step was skipped.
HPLC analysis was performed using Waters Alliance
2965 separation module equipped with Waters 996
Photodiode Array Detector and integrated autosampler.
System control and data processing were performed
using Empower software. Chromatographic separation
was achieved by ACE Excel Super C18 column
(100 3 3 mm, 3 mm) under isocratic conditions with
mobile phase consisting of ACN: 5 mmol/L ammonium
acetate buffer, pH 4.5 (73:27 and 55:45, v/v for
simvastatin and pravastatin samples, respectively).
The flow rate was set at 0.4 mL/min for simvastatin
and 0.3 mL/min for pravastatin samples. Samples
temperature was kept at 4C, and column temperaturewas set at 40C. Chromatographic separation was
monitored by photodiode array detector at 238 nm
with an injection volume of 20 mL.
LCMS/MSanalysis. The intracellular concentrations of
the hydroxy acid and lactone forms of simvastatin and
pravastatin were determined by LC MS/MS method.
A 100 mL of cell suspension was transferred into
1.5 mL Eppendorf tubes, and 50 mL of ammonium ace-
tate buffer (100 mmol/L, pH 4.5) along with 10 mL of
internal standard solutions (LOV-A and LOV-L,
2.5 mg/mL) was added, and samples were vortex mixed
for 30 seconds. Cell lysis was performed using Retsch
MM-301 mixer mill after the addition of 300 mL of
ice-cold ACN. Samples were centrifuged at 15,000g
for 10 minutes at 4C to remove cell debris. After
centrifugation, the ACN layer was transferred into
new glass test tubes, and liquid-liquid extraction was
performed in the same way as described for
HPLC-UV method using methyl tert-butyl ether.
LC MS/MS system consisted of Quattro Ultima
triple-quadrupole mass spectrometer (Micromass, UK)
interfaced via an electrospray ionization probe with
Agilent (1100 Series, Agilent Technologies) HPLC
system. The HPLC system consisted of binary pump,
online degasser, temperature-controlled autosampler,
and column compartment. Chromatographic separation
was achieved by ACE Excel Super C18 column
(100 3 3 mm, 3 mm) with mobile phase consisting of
ACN: 5 mmol/L ammonium acetate buffer, pH 4.5.
An isocratic condition consisted of ACN: ammonium
acetate (80:20, v/v) was used for simvastatin
separation. Pravastatin was separated using gradient
flow as follows: 65% ACN over the first 4 minutes,
increased to 75% ACN over a period of 1 minute and
kept at 75% ACN for another 2 minutes, and then the
flow was returned to 65% ACN in the last minute to
prepare for the next run. The flow rate was set at
0.3 mL/min. Samples temperature was kept at 4C,
and column temperature was set at 40C.
Quantification was performed using multiple-
reaction monitoring scan. The mass spectrometric
system was operated in the negative ionization mode
for quantification of the hydroxy acid forms and positive
mode for determination of the lactone forms. Instrument
control and data acquisition were performed by
MassLynx software packages (version 4.1). Data
processing and analysis were performed using
QuanLynx software. Nitrogen was used for nebulization
and as a dissolution gas, whereas argon was used as a
collision gas. Source temperature and desolvation
temperature were setup at 125 and 350C, respectively.
The flow rate of the cone gas and desolvation gas was set
at 150 and 565 L/h, respectively. Capillary voltage, cone
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individually for each compound as indicated in
Supplementary Table II by direct infusion with mobile
phase using injection pump.
Analytical methods validation. Validation of the
analytical methods was carried out by determining the
intraday and interday accuracy and precision. Six repli-
cates of statin containing samples (human plasma, PBS,
DMEM, and cell lysate) were analyzed at 4 quality
control (QC) levels (lower limit of quantification, low,
medium, and high concentration quality control). Preci-
sion was expressed as relative standard deviation (%),
whereas accuracy was described as relative error (%)
and was determined by comparing the calculated
concentration obtained using calibration curves to the
theoretical concentrations. Intraday and interday preci-
sions and accuracies were calculated by analyzing QC
samples on the same day and on 6 different days over
a period of 1 month, respectively.40-42 The acceptance
criteria for intraday and interday precisions and
accuracies were set at 15% for the high, medium, and
low concentration QC samples and at 20% for lower
limits of quantification.40-42
Extraction recoveries of the lactone and hydroxy acid
forms of statins were also determined at high, medium,
and low QC levels by comparing the peak area ratios of
the analytes spiked after extraction to those spiked
before extraction.43-45 Sex replicates were evaluated at
each QC level.
Expression of cellular transporters. The messenger
RNA (mRNA) expression levels of organic anionic
transporting polypeptide (OATP) OATP1a4 and
OATP2b1 (uptake transporters) and multiresistant
protein (MRP) MRP1, MRP4, and MRP5 (efflux trans-
porters) were assessed using reverse transcriptase PCR
analysis. C2C12 cells were cultured in 10 cm dishes
as described previously. Both undifferentiated and
differentiated cells were maintained in their
corresponding medium of modified pH (relevant to the
physiological pH, acidosis, and alkalosis) for 6 hours.
RNA extraction, cDNA synthesis, and gene
amplifications were performed as described above in
C2C12 growth and differentiation section. The primer
sequences of the transporter and reference genes are
listed in Supplementary Table III. Three different sets
of primers were attempted to amplify OATP1a4 and
OATP2b1 influx transporters. The levels of gene
expressions in undifferentiated and differentiated cell
samples maintained at different pH levels were
calculated relative to their expression in
undifferentiated cells maintained at physiological pH.
Transporters genes were normalized to Gapdh
whereas each reference gene was normalized relative
to the other 3 reference genes. Results were expressedas fold changes in gene expression relative to the
baseline level observed with undifferentiated C2C12
maintained at physiological pH.
In vitro cytotoxicity of statins in mediumwith different pH
levels. The effect of medium pH alteration on the
cytotoxicity of statins was evaluated by MTT and
LDH cytotoxicity assays. Both undifferentiated and
differentiated C2C12 cells were used in these studies.
For MTT assay, cells were seeded at a density of
4,000 cells/well in 96-well plates and allowed to
attach for 24 hours or to differentiate for 4 days.
Before starting treatment, the medium was replaced
by a fresh one with modified pH (6.8, 7.4, and 7.8).
C2C12 cells were treated with different concentrations
of SVL, SVA, PVL, or PVA prepared in dimethyl
sulfoxide (DMSO) for 72 hours. The final level of
DMSO in culture medium was determined by DMSO
tolerance study and was found to be 0.25% (v/v) with
no obvious cytotoxicity (100% viability compared to
untreated cells). Constant volume of DMSO was
maintained for all samples, and DMSO alone without
statins has been used as control. Positive control
samples with 100% cell death were obtained by
treating cells with 1% Triton X-100. Produced
formazan crystals were dissolved in DMSO, and the
absorbance was measured at 570 nm using EnVision
Multilabel Plate Reader (PerkinElmer). Results were
expressed as percentage of the control, and IC50 was
calculated using prism 6 (GraphPad Software Inc).
For LDH assay, cells were cultured and treated as
described previously, and the assay was performed
according to manufacturer instructions. Formation of
red formazan product was monitored at 490 nm with a
reference wavelength of 680 nm. Positive control
samples with 100% LDH release were obtained by fully
lysing the cells before LDH assay to determine the
maximum amount of LDH present in the cells. All
assays were performed in triplicate, and data were
expressed as the ratio of the amount of LDH released,
per treatment, to the maximum amount of LDH released
from the control cells.
Statistical analysis. Data were expressed as
mean 6 SD. Statistical differences between groups
were determined by one-way analysis of variance,
2-way analysis of variance, or Kruskal-Wallis test
followed by Tukey’s, Bonferroni’s, or Dunn’s test for
multiple comparisons, as appropriate. A P-value of less
than 0.05 was considered to be statistically significant.RESULTS
Analytical procedures. Representative chromatogra-
phies and validation data of analytical procedures are
provided in Supplementary Materials.
Fig 2. Interconversion of simvastatin and pravastatin between lactone and hydroxy acid forms in human plasma of
different pH levels. Simvastatin lactone (A), simvastatin hydroxy acid (B), pravastatin lactone (C), and pravastatin
hydroxy acid (D) were incubated with human plasma of modified pH (6.8–7.8) at a concentration of 50 mmol/L for
24 hours at 37C. The percentages of lactone and hydroxy acid form recovered after 24 hours are expressed as
mean 6 standard deviation, (n 5 6). Differences between samples of different pH were analyzed by one-way
analysis of variance followed by Tukey’s post hoc test (***P , 0.001). SVL, simvastatin lactone; SVA,
simvastatin hydroxy acid; PVL, pravastatin lactone; PVA, pravastatin hydroxy acid.
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DMEM culture medium. To characterize the effect of
pH alteration on interconversion of statins, the lactone
and hydroxy acid forms of simvastatin and pravastatin
were incubated with human plasma, PBS, and DMEM
culture medium of pH relevant to acidosis, alkalosis,
and physiological pH for 24 hours. Fig 2 shows the
results of simvastatin and pravastatin interconversion
between lactone and hydroxy acid forms in human
plasma of different pH levels at a concentration of
50 mmol/L. Results indicate that the conversion of the
lactone form of simvastatin and pravastatin to the
corresponding hydroxy acid is strongly pH dependent.
At physiological and alkaline pH, substantial
proportions of SVL (87% and 99%, respectively)
and PVL (98% and 99%, respectively) were
converted to the active hydroxy acid forms after
24 hours of incubation at 37C. At acidic pH, such
conversion occurs to a lower extent, resulting in greater
proportion of statins remaining in the more lipophilic
lactone form (Fig 2, panel A and C). On the other
hand, pH alteration has not been shown to influence the
conversion of the hydroxy acid form to the
corresponding lactone form (Fig 2, panel B and D).Results of statin interconversion between lactone and
hydroxy acid forms in PBS and DMEM culture
medium are shown in Supplementary Figs 1 and 2,
respectively.
Because only the lactone form of statins underwent
pH-dependent conversion, time course conversion
studies were performed for only this form of simvastatin
and pravastatin at a concentration of 50 mmol/L and pH
of 6.8–7.8 over 48 hours in human plasma (Fig 3), PBS
(Supplementary Fig 3), and DMEM culture medium
(Supplementary Fig 4). It is clear that lactone hydrolysis
is both pH- and time-dependent. Even a slight increase
in pH is accompanied by substantial increase in the rate
of hydrolysis to the less lipophilic acid form. This
conversion was observed as early as 30 minutes
(Fig 3, Supplementary Figs 3 and 4). After 48 hours
of incubation with anymatrix of alkaline pH, the lactone
form of simvastatin and pravastatin was almost
completely converted to the hydroxy acid form.
However, at acidic pH, substantial parts of simvastatin
and pravastatin from different matrices remain in the
lactone form. The exception is PVL incubated with hu-
man plasma which shows almost complete conversion
to the hydroxy acid form after 48 hours even under
Fig 3. Time course interconversion of simvastatin lactone (SVL) and pravastatin lactone (PVL) in human plasma
at different pH levels. The lactone forms of simvastatin and pravastatin were incubated with human plasma of
modified pH (6.8–7.8) at a concentration of 50 mmol/L for 48 hours at 37C. The percentages of lactone and
hydroxy acid form recovered at different time points are expressed as mean 6 standard deviation, (n 5 6).
Differences between samples of different pH were analyzed by 2-way analysis of variance followed by
Bonferroni’s post hoc test. Time course interconversion of SVL shows disappearance of SVL (A) and formation
of simvastatin hydroxy acid form (B). a5 pH 7.0 vs pH 7.6 (P, 0.05); pH 7.4 vs pH 6.8, 7.8 (P, 0.01); pH 6.8 vs
pH 7.6, 7.8; pH 7.8 vs pH 7.0, 7.2 (P, 0.001). b5 pH 6.8 vs pH 7.0, 7.2, 7.4, 7.6, 7.8; pH 7.0 vs pH 7.2, 7.4, 7.6,
7.8; pH 7.2 vs pH 7.4, 7.6, 7.8; pH 7.4 vs pH 7.6, 7.8; pH 7.6 vs pH 7.8 (P, 0.001). c5 pH 6.8 vs pH 7.0, 7.2, 7.4,
7.6, 7.8; pH 7.0 vs pH 7.2, 7.4, 7.6, 7.8; pH 7.2 vs pH 7.4, 7.6, 7.8; pH 7.4 vs pH 7.6, 7.8 (P, 0.001); pH 7.6 vs pH
7.8 (P, 0.05). d5 pH 6.8 vs pH 7.0, 7.2, 7.4, 7.6, 7.8; pH 7.0 vs pH 7.2, 7.4, 7.6, 7.8; pH 7.2 vs pH 7.4, 7.6, 7.8
(P, 0.001); pH 7.4 vs pH 7.6 (P, 0.05). e5 pH 6.8 vs pH 7.0, 7.2, 7.4, 7.6, 7.8; pH 7.0 vs pH 7.2, 7.4, 7.6, 7.8;
pH 7.2 vs pH 7.6, 7.8 (P, 0.001); pH 7.4 vs pH 7.2, 7.8 (P, 0.05). Time course interconversion of PVL shows
disappearance of PVL (C) and formation of pravastatin hydroxy acid form (D). a 5 pH 7.6 vs pH 6.8, 7.4
(P , 0.01); pH 7.8 vs pH 6.8, 7.0, 7.2, 7.4; pH 7.2 vs pH 7.6 (P , 0.001). b 5 pH 6.8 vs pH 7.2, 7.4, 7.6, 7.8;
pH 7.0 vs pH 7.2, 7.4, 7.6, 7.8; pH 7.2 vs pH 7.4, 7.6, 7.8; pH 7.4 vs pH 7.6, 7.8; pH 7.6 vs pH 7.8
(P , 0.001). c 5 pH 6.8 vs pH 7.0, 7.2, 7.4, 7.6, 7.8; pH 7.0 vs pH 7.2, 7.4, 7.6, 7.8; pH 7.2 vs pH 7.4, 7.6,
7.8; pH 7.4 vs pH 7.6, 7.8 (P , 0.001). d 5 pH 6.8 vs pH 7.0, 7.2, 7.4, 7.6, 7.8; pH 7.0 vs pH 7.4, 7.6, 7.8
(P , 0.001); pH 7.0 vs pH 7.2 (P , 0.01).
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with PVL incubated with human plasma compared to its
incubation with DMEM and PBS. Contrary to this, the
rate of hydrolysis of SVL was slower in plasma samples
than in DMEM and PBS samples. This was demon-
strated by comparing the hydrolysis half-life of the
lactone form of statins under different pH levels
(Table I). PVL showed the shortest half-life when incu-
bated with human plasma, whereas SVL demonstrated
the longest half-life. Identical interconversion patterns
were reported for each statin over all tested concentra-
tions (12.5, 25, 50, and 100 mmol/L for SVL and SVAand 25, 50, 100, and 200 mmol/L for PVL and PVA)
and within different matrices (data not shown).
Liver microsomal metabolic stability. Stability profiles
of SVL at different pH levels and concentration-time
profiles of SVA form in corresponding reaction
mixtures are depicted in Fig 4, A and B, respectively.
SVL was metabolized at slower rate in the
microsomal reaction mixture at pH 6.8 compared with
other pH conditions; the half-lives (mean 6 SD) were
2.61 6 0.07, 1.28 6 0.05, and 1.23 6 0.01 minutes at
pH 6.8, 7.4, and 7.8, respectively. It is worth
mentioning that the concentration-time profiles of
Fig 4. Liver microsomal stability of simvastatin lactone at 3 different pH levels. (A) Microsomal stability of sim-
vastatin lactone as a function of time at different pH levels; (B) concentration-time profiles of simvastatin hydroxy
acid form detected in liver microsomal stability reaction mixtures at 3 different pH levels. Results are expressed as
mean 6 standard deviation, (n 5 3). Solid line denotes exponential regression of samples at pH 6.8; dashed line
denotes exponential regression of samples at pH 7.4; whereas dotted line denotes exponential regression samples
at pH 7.8.
Table I. The pH dependence of the hydrolysis of the lactone form of statins
Sample pH
Simvastatin lactone (half-life, hours) Pravastatin lactone (half-life, hours)
PBS Human plasma DMEM PBS Human plasma DMEM
6.8 26.68 6 0.97 36.51 6 4.37*,† 21.42 6 2.35* 21.22 6 1.75 8.84 6 0.31*,† 17.30 6 4‡
7.0 16.92 6 0.86 21.30 6 2.50* - 12.96 6 1.38 7.39 6 0.22 -
7.2 13.68 6 0.71 14.46 6 3.55 11.70 6 0.50 9.36 6 1.57 6.61 6 0.95§,† 11.89 6 2.71
7.4 12.86 6 0.31 10.45 6 0.38 7.40 6 0.37* 6.89 6 0.41 6.85 6 0.54i 9.72 6 1.42§
7.6 9.58 6 1.67 9.16 6 1.77 - 5.59 6 0.49 NA -
7.8 10.23 6 1.18 8.61 6 3.38 7.09 6 0.30 4.98 6 0.44 NA 10.66 6 0.81‡
Abbreviations: DMEM, Dulbecco’s modified eagle medium; NA, nonapplicable; PBS, phosphate buffer saline.
Data are presented as mean6 SD of 6 replicates. Statistical analysis was done by 2-way analysis of variance followed by Bonferroni’s post hoc
test.
*Significant difference from PBS samples (P , 0.001).
†Significant difference from DMEM samples (P , 0.001).
‡Significant difference from PBS samples (P , 0.01).
§Significant difference from DMEM samples (P , 0.05).
iSignificant difference from DMEM (P , 0.05).
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of metabolic loss of the lactone, indicating that the
hydroxy acid is not the main metabolite of SVL in the
reaction mixture.
Characterization of myogenic differentiation of
C2C12. Analysis of real-time qPCR results revealed
the presence of marked increase in the expression of
myogenin and MHC genes during C2C12
differentiation (Fig 5, A). Myogenin expression was
increased in the early stage of myoblast
differentiation, reached a maximum of 36-fold the
baseline levels after 3 days and remain elevated
during the subsequent days of differentiation. On the
other hand, a gradual increase in gene expression was
observed with MHC gene, and the levels of expression
reached a maximum of 70-fold by day 7. No
significant changes were reported in the expression of
Gapdh, Hprt and at most time points of Rps12
reference genes during C2C12 cell differentiation
(Fig 5, B).Cellular uptake of statins in response to altered medium
pH. To gain a better understanding of the influence of
pH alteration on statin-induced myotoxicity, time
course uptake studies of SVL, SVA, PVL, and PVA
were performed using undifferentiated and
differentiated C2C12 cells over pH relevant to
acidosis, alkalosis, and physiological conditions.
The effect of medium pH alteration on cellular simva-
statin uptake was assessed by comparing the concentra-
tion of simvastatin recovered from muscle cells
maintained under different pH conditions. Fig 6 shows
the uptake of simvastatin by undifferentiated and
differentiated C2C12 after treatment with 1 mmol/L
SVL or SVA over period of 6 hours. The maximum
cellular uptake of SVL by undifferentiated cells was
reached within 2 hours of treatment. This initial increase
in cellular SVL uptake by muscle cells was followed by
a gradual decline over time (Fig 6, A). During the first 2
hours of treatment, no significant differences in SVL
uptake by undifferentiated cells were found between
Fig 5. qPCR expression profiles of (A) myogenin and myosin heavy chain at days 0–9 of C2C12 differentiation;
(B) glyceraldehyde-3-phosphate dehydrogenase, hypoxanthine-guanine phosphoribosyltransferase and ribosomal
protein S12 reference genes at days 0–9 of C2C12 differentiation. Analysis of gene expression was done after
normalization to single reference gene (TATA box-binding protein) and the fold changes in gene expression
were expressed relative to gene expression in undifferentiated cells. Results are expressed as mean 6 standard
deviation, (n5 3). Data were analyzed by Kruskal-Wallis nonparametric test followed by Dunn’s test for multiple
comparisons. a 5 significant difference in myogenin expression between day 0 and day 3 (P , 0.01);
b5 significant difference in myosin heavy chain expression between day 0 and day 7 (P, 0.01); c5 significant
difference in ribosomal protein S12 expression between day 0 and day 5 (P , 0.05). mRNA, messenger RNA.
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period of time resulted in significant differences in the
cellular SVL uptake at different pH levels as shown
by the changes in the concentration of total simvastatin
(lactone and hydroxy acid forms) recovered in response
to medium pHmodifications (Fig 6, A). The total simva-
statin recovered from undifferentiated cells maintained
at physiological pH after 3, 5, and 6 hours of treatment
was 170.56 23.7, 84.86 4.1, and 99.76 21.4 nmol/mg
protein, respectively. Reducing extracellular pH to
acidic range resulted in a marked increase in total
simvastatin uptake by approximately 50%, 78%, and
40%, respectively, compared with total simvastatin
recovered from cells grown under physiological pH.
On the other hand, no significant differences of SVL
uptake were detected between cells grown under
alkaline and physiological conditions (Fig 6, A). The
intracellular concentrations of SVL recovered from
undifferentiated C2C12 cells were significantly higher
than those of the hydroxy acid form at all tested pH
levels (Supplementary Fig 5, A).
Unlike undifferentiated cells, short-term treatment of
differentiated C2C12 cells with SVL for 2-hour period
resulted in significant changes in simvastatin uptake in
response to medium pH alteration. At physiological
pH, after 2 hours of treatment, SVL uptake by
differentiated C2C12 cells was 210.4 6 7.2 nmol/mg
protein. Acidification of culture medium to a pH of
6.8 significantly increased SVL uptake by 40% relative
to physiological pH, whereas medium alkalinization to
a pH of 7.8 resulted in a significant reduction in SVL
uptake by 27% (Fig 6, B).
Results of cellular uptake of SVA by undifferentiated
and differentiated C2C12 cells under different pHconditions are shown in Fig 6, C and D, respectively.
The uptake of SVA by these cells was much lower
than that of SVL at all time points. Significantly
more SVA (2.5–5 folds) was recovered form
undifferentiated C2C12 cells maintained under acidic
pH compared with cells treated under physiological
conditions. Increasing the extracellular pH to alkaline
level of 7.8 has not been shown to further increase the
uptake of SVA compared to pH 7.4 (Fig 6, C). All
intracellular simvastatin recovered from undifferenti-
ated cells was in the hydroxy acid form, and no SVL
was detected at any pH level.
The uptake of SVA by differentiated C2C12 was
several folds higher than their uptake by undifferenti-
ated cells. Reducing the extracellular pH to acidic levels
significantly increased the uptake of SVA by
differentiated C2C12 cells by more than 2 folds,
whereas maintaining the cells under alkaline pH
significantly reduced their uptake by approximately
50% (Fig 6, D). Unlike undifferentiated cells, it was
possible to observe minor interconversion of SVA to
the corresponding lactone form by differentiated cells
treated under different pH levels (Supplementary
Fig 5, C).
Uptake study was also performed by incubating
undifferentiated and differentiated C2C12 cells with
PVL or PVA (1 mmol/L). As expected, the intracellular
levels of pravastatin were extremely low (below the
limit of quantification of the analytical assay; data not
shown).
Expression of cellular transporters. In the present study,
the expression of mRNA of 2 influx transporters
(OATP1a4 and OATP2b1) and 3 efflux transporters
(MRP1, MRP4, and MRP5) were assessed in
Fig 6. Uptake of simvastatin lactone (SVL) and simvastatin hydroxy acid (SVA) by undifferentiated and
differentiated C2C12 cells. The uptake was determined after incubation of the cells with 1 mmol/L of SVL or
SVA in Dulbecco’s modified eagle medium culture medium of different pH levels (6.8–7.8) at 37C for 6 hours.
Results are expressed as nanomoles per milligram of protein6standard deviation, (n5 5). Data were analyzed by
2-way analysis of variance followed by Bonferroni’s post hoc test. (A) Total simvastatin (lactone1 hydroxy acid)
recovered by undifferentiated C2C12 cells after treatment with 1 mmol/L SVL. a5 pH 6.8 vs pH 7.4 (P, 0.01);
pH 6.8 vs pH 7.8 (P, 0.001); b5 pH 6.8 vs pH 7.4, 7.8 (P, 0.001); c5 pH 6.8 vs pH 7.8 (P, 0.05). (B) Total
simvastatin recovered by differentiated C2C12 cells after treatment with 1 mmol/L SVL. a5 pH 6.8 vs pH 7.4, 7.8
(P, 0.001); pH 7.4 vs pH 7.8 (P, 0.01); b5 pH 6.8 vs pH 7.4 (P, 0.01); pH 6.8 vs pH 7.8 (P, 0.001); c5 pH
6.8 vs pH 7.4, 7.8 (P, 0.01). (C) SVA recovered by undifferentiated C2C12 cells after treatment with 1 mmol/L
SVA (no SVL was recovered in this experiment). a5 pH 6.8 vs pH 7.4 (P, 0.01); pH 6.8 vs pH 7.8 (P, 0.001);
b 5 pH 6.8 vs pH 7.4, 7.8 (P , 0.001). (D) Total simvastatin recovered by differentiated C2C12 cells after
treatment with 1 mmol/L SVA. a 5 pH 6.8 vs pH 7.4, 7.8 (P , 0.001); b 5 pH 6.8 vs pH 7.4, 7.8 (P , 0.001);
pH 7.4 vs pH 7.8 (P , 0.05); c 5 pH 6.8 vs pH 7.4, 7.8 (P , 0.001); pH 7.4 vs pH 7.8 (P , 0.01); d 5 pH
6.8 vs pH 7.4, 7.8; pH 7.4 vs pH 7.8 (P , 0.001).
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tained under different pH conditions. These transporters
have been reported to be involved in statin uptake.46-48
As shown in Supplementary Fig 10,MRP1,MRP4, and
MRP5 were expressed in both cell types. However,
neither OATP1a4 nor OATP2b1 influx transporters
were detected in either cell type. This is consistent
with previous reports that showed no expression of
these influx transporters in undifferentiated and
differentiated C2C12 cells lines.46,48 The mRNA of
both MRP1 and MRP4 efflux transporters were found
to be expressed at higher levels in undifferentiated
cells, whereas MRP5 showed higher expression indifferentiated cells. The pH dependency was found
with MRP1 in undifferentiated cells and with MRP5
in differentiated cells. MRP1 showed higher
expression at acidic pH in undifferentiated cells,
whereas MRP5 exhibited increased levels with
alkaline pH in differentiated cells. Results of mRNA
expression of reference genes are presented in
Supplementary Fig 11.
In vitro cytotoxicity of statins in different medium pH
levels. The effect of medium pH changes on cytotox-
icity of statins was investigated using both undifferenti-
ated and differentiated C2C12 skeletal muscle cells.
Cells were exposed to increasing concentrations of
Fig 7. Effect of simvastatin lactone (SVL) and simvastatin hydroxy acid (SVA) on the viability of undifferentiated
and differentiated C2C12. Cells were cultured at a density of 4,000 cells/well and allowed to attach for 24 hours or
to differentiate for 4 days, then exposed to increasing concentrations of SVL or SVA under acidic, neutral, and
alkaline medium pH for 72 hours. Results are presented as mean 6 standard deviation of 3 experiments,
8 replicates per experiment. Data were analyzed by 2-way analysis of variance followed by Bonferroni’s post
hoc test. (A) Effects of SVL on cell viability of undifferentiated C2C12 myoblasts. a 5 pH 7.8 vs pH 6.8, 7.4
(P , 0.001); b 5 pH 7.8 vs pH 6.8, 7.4; pH 6.8 vs pH 7.4 (P , 0.001). (B) Effects of SVL on cell viability of
differentiated C2C12 myocytes. a 5 pH 6.8 vs pH 7.4 (P , 0.01); pH 6.8 vs pH 7.8 (P , 0.05); b 5 pH 6.8
vs pH 7.4, 7.8; pH 7.4 vs pH 7.8 (P , 0.001); c 5 pH 6.8 vs pH 7.4, 7.8 (P , 0.001); d 5 pH 6.8 vs pH 7.4,
7.8 (P , 0.001); pH 7.4 vs pH 7.8 (P , 0.01); e 5 pH 7.8 vs pH 6.8, 7.4 (P , 0.001). (C) Effects of SVA on
cell viability of undifferentiated C2C12 myoblasts. a 5 pH 6.8 vs pH 7.4 (P , 0.001); pH 7.4 vs pH 7.8
(P , 0.05); b 5 pH 7.8 vs pH 6.8, 7.4 (P , 0.05); c 5 pH 7.4 vs pH 7.8 (P , 0.01); d 5 pH 7.8 vs pH 6.8,
7.4 (P , 0.001); e 5 pH 6.8 vs pH 7.4, 7.8; pH 7.4 vs pH 7.8 (P , 0.001). (D) Effects of SVA on cell viability
of differentiated C2C12myocytes. a5 pH 6.8 vs pH 7.8 (P, 0.001); b5 pH 7.4 vs pH 6.8, 7.8 (P, 0.05); pH 6.8
vs pH 7.8 (P, 0.001); c5 pH 6.8 vs pH 7.4, 7.8 (P, 0.001); pH 7.4 vs pH 7.8 (P, 0.05); d5 pH 6.8 vs pH 7.4,
7.8 (P , 0.001); pH 7.4 vs pH 7.8 (P , 0.01); e 5 pH 6.8 vs pH 7.4, 7.8; pH 7.4 vs pH 7.8 (P , 0.001).
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metabolic activity of the cells was measured using the
MTT test (Figs 7 and 8). The IC50 of SVL in
undifferentiated C2C12 cells grown in DMEM
culture medium of physiological pH was found to
be 0.58 6 0.02 mmol/L. Medium acidification to a
pH of 6.8 significantly reduced the IC50 to
0.44 6 0.02 mmol/L, whereas alkalinizing the medium
to pH 7.8 resulted in significant increase in IC50 to1.13 6 0.04 mmol/L. Similar cytotoxicity pattern was
observed with differentiated C2C12 cells treated with
SVL under different pH conditions (Table II).
Likewise, incubating C2C12 cells with SVA resulted
in cytotoxic response comparable with that observed
with SVL in response to medium pH alteration
(Fig 7). However, the IC50 values of SVA were several
folds higher than that of SVL (Table II). The higher
cytotoxicity of SVA observed at acidic pH was
Fig 8. Effect of pravastatin lactone (PVL) and pravastatin hydroxy acid (PVA) on the viability of undifferentiated
and differentiated C2C12. Cells were cultured at a density of 4,000 cells/well and allowed to attach for 24 hours or
to differentiate for 4 days, then exposed to increasing concentrations of PVL or PVA under acidic, neutral,
and alkaline medium pH for 72 hours. Results are presented as mean 6 standard deviation of 3 experiments,
8 replicates per experiment. Data were analyzed by 2-way analysis of variance followed by Bonferroni’s post
hoc test. (A) Effects of PVL on cell viability of undifferentiated C2C12 myoblasts. a 5 pH 6.8 vs pH 7.8
(P , 0.001); b 5 pH 6.8 vs pH 7.4 (P , 0.05); pH 7.8 vs pH 6.8, 7.4 (P , 0.001); c 5 pH 6.8 vs pH 7.4, 7.8,
pH 7.4 vs pH 7.8 (P , 0.001). (B) Effects of PVL on cell viability of differentiated C2C12 myocytes. a 5 pH
7.4 vs pH 7.8 (P , 0.05); b 5 pH 6.8 vs pH 7.8 (P , 0.01); c 5 pH 6.8 vs pH 7.4, 7.8 (P , 0.001); d 5 pH
6.8 vs pH 7.4, 7.8 (P , 0.001), pH 7.4 vs pH 7.8 (P , 0.01); e 5 pH 6.8 vs pH 7.4, 7.8, pH 7.4 vs pH 7.8
(P , 0.001). (C) Effect of PVA on cell viability of undifferentiated C2C12 myoblasts. a 5 pH 6.8 vs pH 7.8
(P , 0.01); b 5 pH 6.8 vs pH 7.8 (P , 0.001). (D) Effect of PVA on cell viability of differentiated C2C12
myocytes. a 5 pH 6.8 vs pH 7.8 (P , 0.001); pH 7.4 vs pH 7.8 (P , 0.01); b 5 pH 7.8 vs pH 6.8, 7.4
(P , 0.001); c 5 pH 7.8 vs pH 6.8, 7.4 (P , 0.001); pH 6.8 vs pH 7.4 (P , 0.05).
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cytotoxicity of PVL and PVA in both undifferentiated
and differentiated C2C12 was much lower than that of
SVL and SVA after 72 hours of treatment under
different pH conditions (Figs 7 and 8). Interestingly,
undifferentiated C2C12 cells were found to be more
sensitive to statin-induced myotoxicity compared with
differentiated cells (Table II).
The effect of medium pH alteration on cell membrane
integrity was also tested using LDH assay. Results from
LDH release assay are shown in Figs 9 and 10. It is clearthat simvastatin (applied either as lactone or hydroxy
acid form) induces higher LDH leakage from cell
membranes of undifferentiated and differentiated
C2C12 cells than pravastatin over the tested concentra-
tions. Compared with their hydroxy acid counterparts,
the highly lipophilic lactone forms of simvastatin and
pravastatin were shown to induce higher LDH release
especially when cells were maintained under acidic
conditions. The cytotoxicity results obtained with
LDH assay correspond well with the cell viability data
observed with MTT assay.
Table II. Cytotoxicity of statins to C2C12 cells after 72 hours of treatment in medium of different pH. Data are
presented as mean 6 SD of 3 experiments, 8 replicates per experiment
Statin C2C12 cells
IC50 values of statins (mmol/L)
Acidic medium Neutral medium Alkaline medium
Simvastatin lactone Undifferentiated cells 0.44 6 0.02* 0.58 6 0.02† 1.13 6 0.04‡
Differentiated cells 15.79 6 0.77*,§ 40.76 6 1.75†,§ 56.99 6 1.86‡,§
Simvastatin hydroxy acid Undifferentiated cells 2.22 6 0.04* 4.35 6 0.09† 16.85 6 0.48‡
Differentiated cells 65.41 6 2.69§ NA NA
Pravastatin lactone Undifferentiated cells 85.59 6 2.05 NA NA
Differentiated cells 109.9 6 3.74§ NA NA
Abbreviations: NA, non-applicable; SD, standard deviation.
Data are presented as mean 6 SD of 3 experiments, 8 replicates per experiment. Statistical analysis was done by 2-way analysis of variance
followed by Bonferroni’s post hoc test.
*Significant difference from neutral and alkaline medium (P , 0.001).
†Significant difference from acidic and alkaline medium (P , 0.001).
‡Significant difference from acidic and neutral medium (P , 0.001).
§Significant difference from undifferentiated cells (P , 0.001).
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Interconversion of statins in human plasma, PBS, and
DMEM culture medium. Simvastatin has been selected in
this work as a model lipophilic statin because of its wide
clinical use, high lipophilicity, and high incidence of
muscle toxicity.2,33 Pravastatin was selected as a model
hydrophilic statin with expected lower cellular uptake
and myotoxicity. The interconversion of statins between
lactone and hydroxy acid forms was investigated over
concentrations ranging from 12.5 to 100 mmol/L for
SVL and SVA and concentrations of 25 to 200 mmol/L
for PVL and PVA. These concentrations have been
selected based on a review of literature that
described the in vitro experiments of statin-induced
myotoxicity.49-54
In the present study, the lactone forms of simvastatin
and pravastatin were found to be highly susceptible to
pH-dependent conversion to the less lipophilic hydroxy
acid forms. Acidification of human plasma, PBS, and
DMEM culture medium significantly reduced the con-
version of the lactone forms of both statins to the corre-
sponding acid forms. On the other hand, alkalinization
resulted in almost complete conversion of the lactone
form to the active and less myotoxic hydroxy acid
form (Fig 2, panel A and C). It is worth noting that
regardless of the different pH conditions, the hydroxy
acid forms of simvastatin and pravastatin were more sta-
ble than the lactone forms (Fig 2, panel B and D).
Statins are known to have relatively short half-lives in
the range of 1–5 hours.55 However, because the effects
of pH alteration on statin interconversion were observed
within the first 30 minutes of incubation (Fig 3,
Supplementary Figs 3 and 4), changes in plasma pH
are expected to affect statins interconversion within
the general circulation before statin being clearedfrom the body. A slower rate of hydrolysis was reported
when SVLwas incubated with human plasma compared
with DMEM and PBS samples as shown by longer
half-life observed under acidic conditions (Table I).
This finding could be attributed to the binding of SVL
to albumin and other plasma proteins. It has been
reported that SVL is extensively bound to plasma
proteins (95%–98%).55 Such binding reduces the free
(unbound) fraction of SVL, makes it less susceptible
to pH-dependent interconversion, and consequently
slows down its hydrolysis. Similar results were reported
with camptothecin (an anticancer drug which undergoes
a similar pH-dependent interconversion between
lactone and hydroxy acid forms).56,57 On the other
hand, the rate of hydrolysis of PVL from plasma
samples was found to be faster than that from DMEM
and PBS samples probably because of low plasma
protein binding (50%) that render PVL more available
for chemical and enzymatic hydrolysis (by plasma
estreases and paraxonases).58,59
Liver microsomal metabolic stability. Metabolic stabil-
ity studies were performed using human liver
microsomes and potassium phosphate buffer at different
pH levels to simulate acidosis, physiological pH, and
alkalosis. SVL was tested in microsomal stability
experiments because it was found to be the most
cytotoxic statin in our studies. SVL underwent
extensive metabolism at all pH levels, but at
acidic pH, the metabolic rate was 2-fold slower than
that at physiological pH. This result suggests that
at pathophysiological conditions of acidosis, the
metabolism of the lactone form by liver enzymes
could be slower. Therefore, both the slower
metabolism and slower chemical conversion rate of
the lactone form would lead to higher levels of the
Fig 9. Effect of simvastatin lactone (SVL) and simvastatin hydroxy acid (SVA) on lactate dehydrogenase (LDH)
release from undifferentiated and differentiated C2C12 cells maintained under different pH levels. C2C12 cells
were cultured at a density of 4,000 cells/well and allowed to attach for 24 hours or to differentiate for 4 days,
then exposed to increasing concentrations of SVL or SVA under acidic, neutral, and alkaline medium pH. Undif-
ferentiated cells were treated for 72 hours, whereas differentiated cells were maintained for 24 hours. Data are
presented as mean 6 standard deviation, (n 5 3) and analyzed by 2-way analysis of variance followed by Bon-
ferroni’s post hoc test. (A) LDH release from undifferentiated C2C12 cells treated with SVL. a 5 pH 6.8 vs
pH 7.4 (P , 0.001); b 5 pH 6.8 vs pH 7.4, 7.8 (P , 0.001); c 5 pH 6.8 vs pH 7.4, 7.8; pH 7.4 vs pH 7.8
(P , 0.001). (B) LDH release from differentiated C2C12 cells treated with SVL. a 5 pH 6.8 vs pH 7.4, 7.8;
pH 7.4 vs pH 7.8 (P , 0.001). (C) LDH release from undifferentiated C2C12 cells treated with SVA. a 5 pH
6.8 vs pH 7.8 (P , 0.05); b 5 pH 6.8 vs pH 7.4, 7.8; pH 7.4 vs pH 7.8 (P , 0.001); c 5 pH 6.8 vs pH 7.4
(P , 0.01); pH 7.8 vs pH 6.8, 7.4 (P , 0.001). (D) LDH release from differentiated C2C12 cells treated with
SVA. a 5 pH 6.8 vs pH 7.4 (P , 0.01); pH 6.8 vs pH 7.8 (P , 0.05); b 5 pH 6.8 vs pH 7.4, 7.8 (P , 0.0001).
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shows that the levels of formation of SVA do not
correspond to metabolic loss of the lactone form,
which suggests that the hydroxy acid form is not the
main metabolite formed in the microsomal reaction
mixture. It is also evident that SVA is not metabolized
extensively by the liver microsomes, which is in
agreement with previously reported studies.60
Characterization of myogenic differentiation of
C2C12. In this study, successful differentiation of
C2C12 myoblast cells into functioning and integrated
myotubes was confirmed by examining the expression
of 2 markers of myogenic differentiation (myogenin
and MHC). The expression of myogenin started at day
1 after induction of differentiation and reached high
levels at day 3, a stage at which the cells start fusingand form multinucleated myotubes. It has been
suggested that the expression of myogenin (an early
marker for the entry of C2C12 myoblasts into the
differentiation phase) is followed by skeletal
myogenesis through a highly organized sequence of
events that involve withdrawal from cell cycle,
expression of contractile proteins such as myosin heavy
chain, and finally cell fusion resulting in the formation
of multinucleated myotubes.61
On the other hand, the expression of MHC showed a
steady increase over time and reached a maximum of
70-fold the baseline level by the seventh day. In
previously reported study, western blot analysis of a
number of myogenic markers during C2C12 differenti-
ation revealed that the expression of myogenin preceded
the induction of MHC, whose expression showed a
Fig 10. Effect of pravastatin lactone (PVL) and pravastatin hydroxy acid (PVA) on lactate dehydrogenase (LDH)
release from undifferentiated and differentiated C2C12 cells maintained under different pH levels. C2C12 cells
were cultured at a density of 4,000 cells/well and allowed to attach for 24 hours or to differentiate for 4 days,
then exposed to increasing concentrations of PVL or PVA under acidic, neutral, and alkaline medium pH. Undif-
ferentiated cells were treated for 72 hours, whereas differentiated cells were maintained for 24 hours. Data are
presented as mean 6 standard deviation, (n 5 3) and analyzed by 2-way analysis of variance followed by
Bonferroni’s post hoc test. (A) LDH release from undifferentiated C2C12 cells treated with PVL. a 5 pH 7.4
vs pH 7.8 (P , 0.05); b 5 pH 6.8 vs pH 7.8 (P , 0.001); c 5 pH 6.8 vs pH 7.4, 7.8 (P , 0.001); pH 7.4 vs
pH 7.8 (P , 0.05); d 5 pH 6.8 vs pH 7.4, 7.8 (P , 0.001); e 5 pH 6.8 vs pH 7.4, 7.8; pH 7.4 vs pH 7.8
(P , 0.001). (B) LDH release from differentiated C2C12 cells treated with PVL. a 5 pH 6.8 vs pH 7.4, 7.8
(P , 0.01); b 5 pH 6.8 vs pH 7.4, 7.8 (P , 0.001); c 5 pH 6.8 vs pH 7.4, 7.8 (P , 0.001); pH 7.4 vs pH 7.8
(P , 0.05). (C) LDH release from undifferentiated C2C12 cells treated with PVA. a 5 pH 6.8 vs pH 7.8
(P , 0.05); b 5 pH 6.8 vs pH 7.4 (P , 0.01); pH 6.8 vs pH 7.8 (P , 0.001); c 5 pH 6.8 vs pH 7.4, 7.8
(P , 0.001); d 5 pH 6.8 vs pH 7.4, 7.8 (P , 0.001); pH 7.4 vs pH 7.8 (P , 0.05); e 5 pH 6.8 vs pH 7.4, 7.8;
pH 7.4 vs pH 7.8 (P , 0.001). (D) LDH release from differentiated C2C12 cells treated with PVA. a 5 pH 6.8
vs pH 7.8 (P , 0.05).
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Cellular uptake of statins in response to altered medium
pH. High-plasma statin levels have been considered to
be a risk factor for statin-induced myotoxicity.
However, there are patients who exhibit high statin
plasma levels but do not develop myopathy,
suggesting that other factors, including skeletal
muscle fiber statin concentration, may have an impact
on side effect risk.48 In the present study, the
alteration of extracellular pH as a result of acidosis
and alkalosis has been proposed to contribute to
variable uptake of statins by skeletal muscle cells.
Although no pravastatin lactone or hydroxy acid
forms were detected in either undifferentiated anddifferentiated C2C12 cells at any pH levels after
different incubation times, the cellular uptake of
simvastatin was found to be strongly affected by the
pH level of the incubation medium. Incubating
undifferentiated C2C12 cells with SVL for a period
exceeding 2 hours resulted in significantly higher total
simvastatin accumulation within the cells under acidic
condition compared with neutral and alkaline
conditions (Fig 6, A). These findings could be attributed
to the greater proportion of simvastatin that remains in
the more lipophilic lactone form at acidic pH. The
lactone form has higher ability to cross the cell
membranes of muscle cells and achieve high
intracellular concentrations. This could explain
the higher cytotoxicity observed under acidic
Translational Research
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conditions (Table II). It should be noted that the increase
in simvastatin uptake under acidic conditions is also
expected to result in enhanced lipid-lowering activity.
In contrast to acidic conditions, medium alkaliniza-
tion did not influence the cellular uptake of simvastatin
significantly in comparison to the uptake at physiolog-
ical pH. SVL is less stable at alkaline pH and therefore
dynamic equilibrium favors hydrolysis of the lactone
ring to yield the hydrophilic hydroxy acid form. Higher
intracellular concentrations of the lactone than its
corresponding acid form were recovered from undiffer-
entiated cells at all pH levels indicating that cellular
accumulation of simvastatin is associated with its
lipophilic nature (Supplementary Fig 5, A). A marked
difference in lipophilicity exists between lactone and
hydroxy acid forms of statins, with the lactone form
being more lipophilic than the corresponding acid
form.9,11 The lipid-enriched membranes of muscle cells
act as a barrier to hydrophilic statins, whereas it allow
passive diffusion of lipophilic ones.62 It has been sug-
gested that intracellular statin concentrations are also
controlled by the dynamic interplay between uptake
and efflux transporter activities.48 However, it is not
yet clear whether these transporters have differential
selectivity to the acid or lactone forms of statins. It is
worth noting that the intracellular concentrations of
the acid form of simvastatin recovered from
undifferentiated cells were not significantly different
at various pH levels studied, suggesting that
intracellular microenvironment was not influenced by
the extracellular pH changes (Supplementary Fig 5, A).
Similarly, medium acidification increased simvastatin
uptake by differentiated C2C12 cells as a result of
greater proportion of the highly lipophilic lactone
form preserved under acidic conditions (Fig 6, B).
Less SVL was taken up by differentiated C2C12 cells
compared with undifferentiated cells. Although the
reasons for this difference are not entirely clear, the
denser organization of cells as they differentiate could
contribute to lower uptake of the statins by
differentiated C2C12 cells. More studies will be needed
to clarify this mechanism.
Measurement of the intracellular concentrations of
both forms of simvastatin revealed a faster rate of
hydrolysis of the lactone form within differentiated
C2C12 cells compared to undifferentiated cells
(Supplementary Fig 5, A and B).The higher metabolic
rate of differentiated cells could explain the faster rate
of SVL hydrolysis.
SVA has been shown to be taken up by undifferenti-
ated and differentiated C2C12 cells to much lower
extent than SVL (Fig 6, C and D). The higher uptake
of SVA observed under acidic conditions could beattributed to the passive diffusion of the more lipophilic
unionized form of SVA which becomes more
predominant at acidic pH compared with physiological
and alkaline pH.
Expression of cellular transporters. Potential contribu-
tion of drug transporters to cellular uptake and
cytotoxicity of statins over different pH levels was
assessed in this study by measuring the mRNA
expression of influx and efflux transporters that are
known to influence statin uptake. A recent study of
statin myotoxicity has shown that differentiated human
skeletal muscle cells constitutively express MRP
transporters (namely MRP1, MRP4, and MRP5) which
mediate the efflux of statins from skeletal muscle fibers.
Expression of these efflux transporters combined with
the inability of differentiated muscle cells grown
in vitro to express OATPs influx transporters could
potentially play protective roles against intracellular
statin accumulation.48 Similar to previously reported
studies,46,48 the levels of mRNA expression of influx
transporters (OATP1a4 and OATP2b1) were not
detectable in our experiments. MRP5 was found to
have higher expression in differentiated cells
compared to undifferentiated cells which could
explain the relative resistance of former cells to
statin-induced cytotoxicity. Moreover, it was found to
be expressed at a lower level at pH 6.8, where higher
cytotoxicity was observed (Supplementary Fig 10).
On the other hand, the mRNA expression of MRP1
and MRP4 transporter genes appear to be greater
in undifferentiated compared with differentiated
C2C12 cells.
Taken together, the results suggest that although
MRP5 could play some role in the intracellular accumu-
lation of simvastatin, overall, the results of expression
of transporters do not explain the intracellular
accumulation of statins. Therefore, it is likely that
passive diffusion of the more lipophilic lactone form
is a primary mechanism of intracellular accumulation
of statins, especially in acidic conditions.
In vitro cytotoxicity of statins in different medium pH
levels. MTTassay. For the cells to have a normal function
and metabolism, the pH should be maintained within
narrow limits of 7.35–7.45. Disturbances in acid-base
balance impose profound effects on many aspects of
drug action.63 Our results demonstrated that alteration
in culture medium pH greatly influenced the cytotox-
icity of statins (Figs 7 and 8). The higher cytotoxicity
of SVL found in C2C12 cells treated under acidic
conditions could be attributed to the higher proportion
of statin that remained in the more lipophilic lactone
form. Low cytotoxicity under alkaline condition could
be due to inability of statins to achieve adequate
intracellular concentrations as a result of conversion to
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is about 3 times more lipophilic than its corresponding
hydroxy acid form9 and is, therefore, expected to
achieve higher intracellular concentrations. Enhanced
cytotoxicity of SVA has also been demonstrated at
acidic pH, which could be due to the passive transport
mechanisms of the predominantly unionized hydroxy
acid form in acidic environment.64 Hydrophilic
pravastatin was shown to be less cytotoxic than
lipophilic simvastatin. Undifferentiated C2C12 cells
were found to be more sensitive to simvastatin-
induced myotoxicity compared with differentiated cells
(Table II). These findings suggest that multinuclear
skeletal muscle cells are more resistant to
statin-induced myotoxicity compared with mononu-
clear stem cells. Although SVL is inactive with respect
to lipid-lowering effect, it may still mediate muscular
side effects, either through a direct toxic effect or
through intracellular conversion to the hydroxy
methyl glutaryl-Co enzyme A reductase–inhibiting
acid form.12
LDH cytotoxicity assay. In the present study, LDH has
been used to reflect the cell membrane integrity in
response to cell exposure to statin therapy. The amounts
of LDH release induced by statins treatment over
different pH levels are shown in Figs 9 and 10. The
cytotoxicity detected with LDH assay was in agreement
with the cell viability profiles obtained with MTTassay.
Similar LDH release pattern was observed with both
simvastatin and pravastatin in response to medium pH
alteration. A significant increase in LDH release was
observed when cells were exposed to statins under
acidic conditions compared with physiological and
alkaline conditions. The LDH release was higher from
C2C12 cells treated with simvastatin compared with
pravastatin treated cells. Furthermore, the lactone forms
of both statins have induced higher LDH release than
the corresponding acid form. The higher release of
LDH by statins under acidic conditions is expected to
be due to the higher cellular uptake of the more
lipophilic lactone form.CONCLUSIONS
This work demonstrates that acid-base imbalance
affects the interconversion of statins between the
lactone and hydroxy acid forms. The conversion of
lactone form of statins to the corresponding hydroxy
acid form is strongly pH dependent. At physiological
and alkaline pH, the lactone form undergoes substantial
conversion while this conversion occurs at lower extent
under acidic conditions. On the contrary, the conversion
of the hydroxy acid form to the corresponding
lactone form is negligible at any pH level. Our dataalso demonstrate that lipophilic SVL is more cytotoxic
to undifferentiated and differentiated skeletal muscle
cells than more hydrophilic SVA, PVL, and PVA.
Furthermore, undifferentiated C2C12 cells are more
sensitive to statin-induced myotoxicity than differenti-
ated muscle cells. Physiological pH and alkalosis can
protect against statin-induced myotoxicity, whereas
acidosis enhances statin-induced myotoxicity as
demonstrated by increased cellular uptake of statins
under acidic conditions. These findings provide novel
insight into the mechanisms of statin-induced
myotoxicity in the presence of acidosis and alkalosis.
By minimizing the chemical and enzymatic hydrolysis
of the lactone form, acidosis can enhance statins uptake
by the skeletal muscle cells and consequently potentiate
their myotoxicity. On the other hand, alkalosis can
potentiate the hydrolysis of the lactone ring rendering
statins less lipophilic and therefore limits their penetra-
tion into the skeletal muscles and increases their uptake
by the liver. Our findings suggest more selective and
conservative approach, as well as tighter monitoring
of statin-related skeletal muscle symptoms when
prescribing lipophilic statins to patients who are at
risk of developing acidosis.ACKNOWLEDGMENTS
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Supplementary Fig 2. Interconversion of statins between lactone and hydroxy acid forms in Dulbecco’s modified
eagle medium culture medium at different pH levels. Simvastatin lactone (A), simvastatin hydroxy acid (B), pra-
vastatin lactone (C), and pravastatin hydroxy acid (D) were incubated with Dulbecco’s modified eagle medium
culture medium of modified pH (6.8–7.8) at a concentration of 50 mmol/L for 24 hours at 37C. The percentages
of the lactone and hydroxy acid form recovered after 24 hours are expressed asmean6 standard deviation, (n5 6).
Differences between samples of different pH were analyzed by one-way analysis of variance followed by Tukey’s
post hoc test (***P, 0.001). SVL, simvastatin lactone; SVA, simvastatin hydroxy acid; PVL, pravastatin lactone;
PVA, pravastatin hydroxy acid.
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Supplementary Fig 3. Time course interconversion of simvastatin lactone (SVL) and pravastatin lactone (PVL)
in phosphate buffer saline at different pH levels. The lactone forms of simvastatin and pravastatin were incubated
with phosphate buffer saline of modified pH (6.8–7.8) at a concentration of 50 mmol/L for 48 hours at 37C. The
percentages of lactone and hydroxy acid form recovered at different time points are expressed as mean6 standard
deviation, (n5 6). Differences between samples of different pH were analyzed by 2-way analysis of variance fol-
lowed by Bonferroni’s post hoc test. Time course interconversion of SVL shows disappearance of SVL (A) and
formation of simvastatin hydroxy acid form (B). a 5 pH 7.8 vs pH 6.8, 7.0 (P , 0.001); pH 7.8 vs pH 7.2
(P , 0.05). b 5 pH 6.8 vs pH 7.2, 7.4, 7.6, 7.8; pH 7.0 vs pH 7.2, 7.4, 7.6, 7.8; pH 7.2 vs pH 7.6, 7.8; pH 7.4
vs pH 7.6, 7.8; pH 7.6 vs pH 7.8 (P , 0.001); pH 7.2 vs pH 7.4 (P , 0.05). c 5 pH 6.8 vs pH 7.0, 7.2, 7.4,
7.6, 7.8; pH 7.0 vs pH 7.2, 7.4, 7.6, 7.8; pH 7.2 vs pH 7.4, 7.6, 7.8; pH 7.4 vs pH 7.6, 7.8; pH 7.6 vs pH 7.8
(P , 0.001). d 5 pH 6.8 vs pH 7.0, 7.2, 7.4, 7.6, 7.8; pH 7.0 vs pH 7.2, 7.4, 7.6, 7.8; pH 7.2 vs pH 7.4, 7.6,
7.8; pH 7.4 vs pH 7.8 (P , 0.001); pH 7.4 vs pH 7.6 (P , 0.01); pH 7.6 vs pH 7.8 (P , 0.05). e 5 pH 6.8 vs
pH 7.0, 7.2, 7.4, 7.6, 7.8; pH 7.0 vs pH 7.2, 7.4, 7.6, 7.8; pH 7.2 vs pH 7.4, 7.6, 7.8 (P , 0.001); pH 7.4 vs pH
7.8 (P , 0.05). f 5 pH 6.8 vs pH 7.0, 7.2, 7.4, 7.6, 7.8; pH 7.0 vs pH 7.2, 7.4, 7.6, 7.8; pH 7.2 vs pH 7.4, 7.6,
7.8 (P, 0.001). g5 pH 6.8 vs pH 7.0, 7.2, 7.4, 7.6, 7.8; pH 7.0 vs pH 7.2, 7.4, 7.6, 7.8 (P, 0.001). Time course
interconversion of PVL shows disappearance of PVL (C) and formation of pravastatin hydroxy acid form (D).
a 5 pH 6.8 vs pH 7.6, 7.8; pH 7.0 vs pH 7.6, 7.8; pH 7.2 vs pH 7.8 (P , 0.001); pH 7.4 vs pH 6.8, 7.8; pH
7.2 vs pH 7.6 (P , 0.01); pH 7.0 vs pH 7.4 (P , 0.05). b 5 pH 6.8 vs pH 7.0, 7.2, 7.4, 7.6, 7.8; pH 7.0 vs pH
7.4, 7.6, 7.8; pH 7.2 vs pH 7.4, 7.6, 7.8; pH 7.4 vs pH 7.6, 7.8 (P , 0.001); pH 7.0 vs pH 7.2 (P , 0.01).
c 5 pH 6.8 vs pH 7.2, 7.4, 7.6, 7.8; pH 7.0 vs 7.2, 7.4, 7.6, 7.8; pH 7.2 vs pH 7.4, 7.6, 7.8 (P , 0.001); pH 6.8
vs pH 7.0 (P , 0.01); pH 7.4 vs pH 7.6 (P , 0.05). d 5 pH 6.8 vs pH 7.0, 7.2, 7.4, 7.6, 7.8; pH 7.0 vs pH 7.4,
7.6, 7.8; pH 7.2 vs pH 7.4, 7.6, 7.8 (P , 0.001). e 5 6.8 vs pH 7.0, 7.2, 7.4, 7.6, 7.8; pH 7.0 vs pH 7.4, 7.6,
7.8; pH 7.2 vs pH 7.6, 7.8, (P , 0.001); pH 7.4 vs pH 7.8 (P , 0.01); pH 7.2 vs pH 7.4 (P , 0.05). f 5 pH
6.8 vs pH 7.0, 7.2, 7.4, 7.6, 7.8; pH 7.0 vs pH 7.4, 7.6, 7.8 (P , 0.001). g 5 pH 6.8 vs pH 7.0, 7.2, 7.4, 7.6,
7.8 (P , 0.001).
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Supplementary Fig 4. Time course interconversion of simvastatin lactone (SVL) and pravastatin lactone (PVL)
in Dulbecco’s modified eagle medium culture medium at different pH levels. The lactone forms of simvastatin and
pravastatin were incubated with Dulbecco’s modified eagle mediumculture medium of modified pH (6.8–7.8) at a
concentration of 50 mmol/L for 48 hours at 37C. The percentages of lactone and hydroxy acid form recovered at
different time points are expressed as mean 6 standard deviation, (n 5 6). Differences between samples of
different pH were analyzed by 2-way analysis of variance followed by Bonferroni’s post hoc test. Time course
interconversion of SVL shows disappearance of SVL (A) and formation of simvastatin hydroxy acid form (B).
a 5 pH 7.8 vs pH 6.8, 7.2 (P , 0.01). b 5 pH 6.8 vs pH 7.2 (P , 0.05); pH 6.8 vs pH 7.4, 7.8; pH 7.2 vs pH
7.4, 7.8; pH 7.4 vs pH 7.8 (P , 0.001). c 5 pH 6.8 vs pH 7.2, 7.4, 7.8; pH 7.2 vs pH 7.4, 7.8; pH 7.4 vs 7.8
(P , 0.001). d 5 pH 6.8 vs pH 7.2, 7.4, 7.8; pH 7.2 vs pH 7.4, 7.8 (P , 0.001); pH 7.4 vs 7.8 (P , 0.01).
e 5 pH 6.8 vs pH 7.2, 7.4, 7.8; pH 7.2 vs pH 7.4, 7.8 (P , 0.001). f 5 pH 6.8 vs pH 7.2, 7.4, 7.8 (P , 0.001).
Time course interconversion of PVL shows disappearance of PVL (C) and formation of pravastatin hydroxy
acid form (D). a 5 pH 6.8 vs pH 7.8 (P , 0.01); pH 7.2 vs pH 7.8 (P , 0.05). b 5 pH 6.8 vs pH 7.2, 7.4, 7.8;
pH 7.8 vs pH 7.2, 7.4 (P , 0.001). c 5 6.8 vs pH 7.2, 7.4, 7.8; pH 7.2 vs 7.8 (P , 0.001); pH 7.2 vs pH 7.4
(P , 0.05). d 5 pH 6.8 vs pH 7.2, 7.4, 7.8 (P , 0.001). e 5 pH 6.8 vs pH 7.4, 7.8 (P , 0.001); pH 6.8 vs pH
7.2 (P , 0.05).
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Supplementary Fig 5. Uptake of simvastatin by undifferentiated and differentiated C2C12 cells. The uptake was
determined after incubation of the cells with 1 mmol/L of simvastatin lactone (SVL) or simvastatin hydroxy acid
(SVA) in Dulbecco’s modified eagle medium of different pH levels (6.8–7.8) at 37C for 6 hours. Results are ex-
pressed as nanomoles per milligram of protein6 standard deviation, (n5 5). Data were analyzed by 2-way anal-
ysis of variance followed by Bonferroni’s post hoc test. (A) Intracellular concentration of simvastatin acid and
lactone recovered from undifferentiated cells after treatment with 1 mmol/L SVL. a 5 SVL, pH 6.8 vs SVA,
pH 6.8; SVL, pH 7.4 vs SVA, pH 7.4 (P , 0.001); b 5 SVL, pH 6.8 vs SVA, pH 6.8; SVL, pH 7.4 vs SVA,
pH 7.4; SVL, pH 7.8 vs SVA, pH 7.8 (P , 0.001); c 5 SVL, pH 6.8 vs SVA, pH 6.8; SVL, pH 7.4 vs SVA,
pH 7.4 (P , 0.001); SVL, pH 7.8 vs SVA, pH 7.8 (P , 0.01). (B) Intracellular concentration of simvastatin
acid and lactone recovered from differentiated cells after treatment with 1 mmol/L SVL. a 5 SVL, pH 6.8 vs
SVA, pH 6.8 (P , 0.001). (C) Intracellular concentration of simvastatin acid and lactone recovered from differ-
entiated cells after treatment with 1 mmol/L SVA. a5 SVA, pH 6.8 vs SVL, pH 6.8; SVA, pH 7.4 vs SVL, pH 7.4
(P , 0.001); b 5 SVA, pH 6.8 vs SVL, pH 6.8; SVA, pH 7.4 vs SVL, pH 7.4; SVA, pH 7.8 vs SVL, pH 7.8
(P , 0.001); c 5 SVA, pH 6.8 vs SVL, pH 6.8; SVA, pH 7.4 vs SVL, pH 7.4 (P , 0.001); SVA, pH 7.8 vs
SVL, pH 7.8 (P , 0.01).
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Supplementary Fig 6. HPLC chromatograms of (A) SVA spiked into Dulbecco’s modified eagle medium
(pH 7.4) with internal standard (IS 5 4,4-dichlorodiphenyltrichloroethane), (B) SVL spiked into Dulbecco’s
modified eagle medium (pH 7.4) with internal standard (IS5 4,4-dichlorodiphenyltrichloroethane), (C) blank cul-
ture medium. SVA, simvastatin hydroxy acid; SVL, simvastatin lactone; IS, internal standard.
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Supplementary Fig 7. HPLC chromatograms of (A) PVA spiked into Dulbecco’s modified eagle medium
(pH 7.4) with internal standard (IS 5 griseofulvin), (B) PVL spiked into Dulbecco’s modified eagle medium
(pH 7.4) with internal standard (IS 5 griseofulvin), (C) blank culture medium. PVA, pravastatin hydroxy acid;
PVL, pravastatin lactone; IS, internal standard.
Translational Research
160.e6 Taha et al August 2016
Time
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00
%
0
2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00
%
0
150423-DTM-3 2: MRM of 2 Channels ES+ 
TIC
9.40e5
5.17
419.29
4.23
427.15
4.25
427.15
150423-DTM-3 1: MRM of 2 Channels ES- 
TIC
1.67e6
2.50
435.49
2.25
421.08
SVL
LOV-L
SVA
LOV-A
Supplementary Fig 8. LC-MS/MS chromatograms of a mixture of measured analytes from cell lysate samples.
LOV-A, lovastatin hydroxy acid (IS); SVA, simvastatin hydroxy acid; LOV-L, lovastatin lactone (IS); SVL,
simvastatin lactone; IS, internal standard.
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Supplementary Fig 9. LC MS/MS chromatograms of a mixture of measured analytes from cell lysate samples.
PVA, pravastatin hydroxy acid; PVL, pravastatin lactone; LOV-A, lovastatin hydroxy acid (IS); LOV-L, lovastatin
lactone (IS); IS, internal standard.
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Supplementary Fig 10. Messenger RNA expression of (A)MRP1, (B)MRP4, and (C)MRP5 in undifferentiated
and differentiated C2C12 cells maintained at different pH levels. Results are expressed as fold changes in gene
expression relative to the baseline level observed with undifferentiated C2C12 maintained at physiological pH
and were normalized relative to Gapdh. Data are presented as mean 6 standard deviation, (n 5 4) and were
analyzed by 2-way analysis of variance followed by Bonferroni’s post hoc test, ***P , 0.001, **P , 0.01,
*P , 0.05. Solid lines denote differences in relative messenger RNA levels between undifferentiated and differ-
entiated cells, whereas dashed lines denote differences within each cell type maintained at different pH levels.
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Supplementary Fig 11. Messenger RNA expression of (A) ribosomal protein S12, (B) hypoxanthine phosphor-
ibosyltransferase, (C) TATA box-binding protein, and (D) glyceraldehyde-3-phosphate dehydrogenase reference
genes. Results are expressed as fold changes in gene expression relative to the baseline level observed with undif-
ferentiated C2C12 maintained at physiological pH. Each reference gene was normalized to the other 3 reference
genes. Data are presented as mean 6 standard deviation, (n 5 4) and were analyzed 2-way analysis of variance
followed by Bonferroni’s post hoc test, ***, §§§, †††P , 0.001, **, §§P , 0.01, *, §, †P , 0.05 compared with
messenger RNA expression level in undifferentiated cell samples of pH 7.4.
Supplementary Table I. Primers used for gene expression quantification of differentiation markers
Gene Direction Primer sequence (50-30) Melting temperature (C) Amplicon length (bp)*
Myogenin Forward CAGGAGATCATTTGCTCG 55.2 122
Reverse GGGCATGGTTTCGTCTGG 62.5
MHC Forward AGGGAGCTTGAAAACGAGGT 60.2 260
Reverse GCTTCCTCCAGCTCGTGCTG 65.9
Tbp Forward TGCACAGGAGCCAAGAGTGAA 64.4 132
Reverse CACATCACAGCTCCCCACCA 65.6
Gapdh Forward ATGTTTGTGATGGGTGTGAA 57.2 151
Reverse ATGCCAAAGTTGTCATGGAT 57.9
Hprt Forward ATGGACTGATTATGGACAGGACTG 61.5 124
Reverse TCCAGCAGGTCAGCAAAGAAC 62.8
Rps12 Forward AAGGCATAGCTGCTGGAGGTGTAA 65.3 156
Reverse AGTTGGATGCGAGCACACACAGAT 67.4
*bp 5 base pairs.
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Supplementary Table II. Optimized LC MS/MS parameters used for analysis of statins
Compound Precursor type Parent ion m/z Daughter ion m/z Capillary voltage (kV) Cone voltage (V) Collision energy (eV)
SVL [M1H]1 419.29 119.17 4.00 35 23
SVA [M-H]2 435.49 319.43 3.20 45 14
PVL [M1H]1 407.46 183.22 3.5 35 18
PVA [M-H]2 423.23 321.37 3.2 35 16
LOV-L [M1Na]1 427.15 325.36 4.00 35 23
LOV-A [M-H]2 421.08 319.54 3.20 45 14
Abbreviations: LOV-A, lovastatin acid; LOV-L, lovastatin lactone; PVA, pravastatin hydroxy acid; PVL, pravastatin lactone; SVA, simvastatin hy-
droxy acid; SVL, simvastatin lactone.
SupplemenItary Table III. Primers used for gene expression quantification of cellular transporters
Gene Direction Primer sequence (50-30) Melting temperature (C)
Amplicon length
(bp)*
MRP1 Forward GTTATGGAAGCCTGTGCCCT 60.03 296
Reverse ATGACATCCACTTGGGGCAG 60.03
MRP4 Forward CCTGGTGAGTTGTTAGCCGT 59.97 326
Reverse AGGTTCACCCGAGCTTTCTG 59.96
MRP5 Forward CTTCCTGGGATCAGCGGTTT 60.04 244
Reverse GCTCTGAAAGTACCCGGCTT 60.04
OATP1a4 Forward AACTCCCATCATGCCCTTGG 60.03 246
Reverse CCTGCACAGACCAAAAAGCC 59.97
OATP2b1 Forward GCCAGAAGGAGGCATCAACT 60.03 233
Reverse TTAAAGGCTCGTGCTGGGAG 60.04
OATP1a4 Forward CTCACTTGGCTGTGATTCTTGT 58.86 254
Reverse TCTTCTGATTGTCTCCAAATGTCT 57.88
OATP2b1 Forward TCATCCTGAGAGGTGTGAAGAAAG 60.02 203
Reverse TATGAATCGGTTTCGGAGCAGG 60.48
OATP1a4 Forward CCACGTCTGTAGTTGGGCTT 59.97 291
Reverse TCACACACTCTGTTGGGTCT 58.50
OATP2b1 Forward TGCCAGAAGGAGGCATCAAC 60.32 346
Reverse ACCAGCAAGAAGATGGGGTG 59.96
Gapdh Forward TGTGAACGGATTTGGCCGTA 59.96 159
Reverse ACTGTGCCGTTGAATTTGCC 59.97
Hprt Forward AGTCCCAGCGTCGTGATTAG 59.54 170
Reverse TGATGGCCTCCCATCTCCTT 60.33
Rps12 Forward ACAAGAGGTGCTGAAGACCG 59.97 275
Reverse CTACGCAACTGCAACCAACC 60.04
Tbp Forward CTCAGTTACAGGTGGCAGCA 59.96 118
Reverse GCACAGAGCAAGCAACTCAC 60.04
*bp 5 base pairs.
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Supplementary Table IV. Intraday and interday precision and accuracy of HPLC methods used for
determination of statins in human plasma samples. Both intraday and interday assay variability values were
within acceptance criteria for all tested compounds at the 4 QC levels
Statins
Quality control levels Intraday (n 5 6) Interday (n 5 6)
Concentration
(mmol/L)
Concentration
(mg/mL)
Precision
(RSD%)*
Accuracy
(RE%)†
Precision
(RSD%)
Accuracy
(RE%)
Simvastatin lactone LLOQ (0.156) 0.065 9.70 25.94 14.56 23.05
LQC (5) 2.09 3.74 210.13 14.79 23.12
MQC (60) 25.12 12.43 0.57 14.30 0.50
HQC (120) 50.23 9.78 21.36 14.44 5.90
Simvastatin hydroxy acid LLOQ (0.313) 0.142 11.61 9.98 11.58 17.42
LQC (5) 2.26 14.83 0.37 10.91 21.33
MQC (60) 27.21 6.54 26.14 6.43 22.45
HQC (120) 54.43 6.72 211.70 7.69 28.93
Pravastatin lactone LLOQ (0.234) 0.095 3.33 13.88 6.95 14.65
LQC (10) 4.06 2.38 23.17 6.99 29.67
MQC (100) 40.65 12.46 2.34 11.74 5.21
HQC (200) 81.30 4.43 6.91 7.27 8.16
Pravastatin hydroxy acid LLOQ (0.469) 0.209 17.39 29.86 16.02 24.53
LQC (10) 4.46 8.35 12.51 8.17 11.50
MQC (100) 44.65 11.84 210.22 13.45 210.71
HQC (200) 89.30 9.85 212.94 10.46 211.32
Abbreviations: HQC, high concentration quality control; LLOQ, lower limit of quantification; LQC, low concentration quality control;MQC, me-
dium concentration quality control.
*Relative standard deviation (RSD%) 5 (standard deviation [SD]/mean of obtained concentration) 3 100.
†Relative error (RE%) 5 ([measured concentration2nominal concentration]/nominal concentration) 3 100.
Supplementary Table V. Intraday and interday precision and accuracy of HPLC methods used for
determination statins in PBS samples. Both intraday and interday assay variability values were within
acceptance criteria for all tested compounds at the 4 QC levels
Statins
Quality control levels Intraday (n 5 6) Interday (n 5 6)
Concentration
(mmol/L)
Concentration
(mg/mL)
Precision
(RSD%)*
Accuracy
(RE%)†
Precision
(RSD%)
Accuracy
(RE%)
Simvastatin lactone LLOQ (0.156) 0.065 1.36 27.04 7.91 15.80
LQC (5) 2.09 4.51 20.81 3.92 211.04
MQC (60) 25.12 11.89 28.30 13.49 9.62
HQC (120) 50.23 10.39 26.69 10.16 28.67
Simvastatin hydroxy acid LLOQ (0.313) 0.142 3.75 26.69 11.60 219.38
LQC (5) 2.26 8.39 213.58 13.55 6.56
MQC (60) 27.21 12.01 9.41 9.88 6.14
HQC (120) 54.43 9.65 21.8 10.75 20.53
LLOQ (0.234) 0.095 4.16 7.06 19.92 22.66
Pravastatin lactone LQC (10) 4.06 2.45 9.66 2.71 14.11
MQC (100) 40.65 5.92 9.35 7.05 23.10
HQC (200) 81.30 5.28 14.57 6.18 21.46
Pravastatin hydroxy acid LLOQ (0.469) 0.209 2.12 19.99 14.32 215.86
LQC (10) 4.46 3.52 8.81 8.39 13.08
MQC (100) 44.65 4.50 7.56 4.86 1.79
HQC (200) 89.30 12.69 4.79 4.93 2.29
Abbreviations: HQC, high concentration quality control; LLOQ, lower limit of quantification; LQC, low concentration quality control;MQC, me-
dium concentration quality control; PBS, phosphate buffer saline.
*Relative standard deviation (RSD%) 5 (standard deviation [SD]/mean of obtained concentration) 3 100.
†Relative error (RE%) 5 ([measured concentration2nominal concentration]/nominal concentration) 3 100.
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Supplementary Table VI. Intraday and interday precision and accuracy of HPLC methods used for
determination of statins in DMEM culture medium samples. Both intraday and interday assay variability values
were within acceptance criteria for all tested compounds at the 4 QC levels
Statins
Quality control levels Intraday (n 5 6) Interday (n 5 6)
Concentration
(mmol/L)
Concentration
(mg/mL)
Precision
(RSD%)*
Accuracy
(RE%)†
Precision
(RSD%)
Accuracy
(RE%)
Simvastatin lactone LLOQ (0.156) 0.065 2.06 7.36 17.28 23.25
LQC (5) 2.09 10.13 6.83 11.82 3.8
MQC (40) 16.74 2.36 23.34 9.35 11.15
HQC (120) 50.23 6.71 22.71 10.13 0.41
Simvastatin hydroxy acid LLOQ (0.313) 0.142 3.99 218.51 11.48 215.85
LQC (5) 2.26 11.97 6.67 12.7 1.97
MQC (40) 18.14 11.47 212.34 9.44 214.98
HQC (120) 54.43 2.68 25.3 3.54 24.16
Pravastatin lactone LLOQ (0.234) 0.095 8.14 17.37 8.87 18.54
LQC (10) 4.06 7.87 6.59 4.07 12.59
MQC (100) 40.65 1.6 26.71 1.5 24.67
HQC (200) 81.30 3.63 25.66 4.2 22.74
Pravastatin hydroxy acid LLOQ (0.469) 0.209 7.28 23.05 18.19 28.12
LQC (10) 4.46 3.42 24.19 1.64 27.99
MQC (100) 44.65 1.54 2.01 1.19 1.29
HQC (200) 89.30 7.13 25.56 9.75 23.37
Abbreviations: DMEM, Dulbecco’s modified eagle medium; HQC, high concentration quality control; LLOQ, lower limit of quantification; LQC,
low concentration quality control; MQC, medium concentration quality control.
*Relative standard deviation (RSD%) 5 (standard deviation [SD]/mean of obtained concentration) 3 100.
†Relative error (RE%) 5 ([measured concentration2nominal concentration]/nominal concentration) 3 100.
Supplementary Table VII. Intraday and interday precision and accuracy of LC MS/MS methods used for
determination of statins in cell lysate samples. Both intraday and interday assay variability values were within
acceptance criteria for all tested compounds at the 4 QC levels
Statins
Quality control levels Intraday (n 5 6) Interday (n 5 6)
Concentration
(nmol/L)
Concentration
ng/mL
Precision
(RSD%)*
Accuracy
(RE%)†
Precision
(RSD%)
Accuracy
(RE%)
Simvastatin lactone LLOQ (5) 2.09 14.34 10.06 15.89 9.60
LQC (20) 8.37 12.35 7.44 13.70 21.79
MQC (200) 83.72 12.91 5.47 10.71 9.24
HQC (2000) 837.17 12.45 8.30 10.52 3.93
Simvastatin hydroxy acid LLOQ (2.5) 1.13 7.215 23.17 9.30 0.16
LQC (20) 9.07 4.69 8.75 5.18 9.52
MQC (200) 90.72 5.12 3.51 6.59 4.77
HQC (2000) 907.24 8.38 25.44 8.19 27.57
Pravastatin lactone LLOQ (5) 2.03 9.98 14.16 6.96 10.00
LQC (20) 8.13 11.46 24.73 11.64 22.20
MQC (200) 81.3 11.36 0.03 9.43 3.72
HQC (2000) 813 7.3 20.20 6.28 20.11
Pravastatin hydroxy acid LLOQ (5) 2.23 17.04 7.30 12.93 11.62
LQC (20) 8.93 11.76 26.32 12.38 26.87
MQC (200) 89.30 12.28 29.45 12.01 23.61
HQC (2000) 893.02 11.10 0.08 8.79 0.03
Abbreviations: HQC, high concentration quality control; LLOQ, lower limit of quantification; LQC, low concentration quality control;MQC, me-
dium concentration quality control.
*Relative standard deviation (RSD%) 5 (standard deviation [SD]/mean of obtained concentration) 3 100.
†Relative error (RE%) 5 ([measured concentration2nominal concentration]/nominal concentration) 3 100.
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Supplementary Table VIII. Extraction recovery (%) of statins from human plasma, PBS, and DMEM samples
Statins Quality control levels
% Of statin recovered (mean 6 SD, n 5 6)
Plasma samples PBS samples DMEM samples
Simvastatin lactone LQC 80.75 6 14.89 96.80 6 6.04 94.48 6 2.76
MQC 89.14 6 7.40 96.28 6 11.12 93.41 6 2.94
HQC 87.52 6 13.50 92.94 6 12.23 82.68 6 7.48
Simvastatin hydroxy acid LQC 87.61 6 16.11 90.15 6 12.3 94.43 6 3.77
MQC 84.61 6 15.74 86.66 6 14.98 70.82 6 6.81
HQC 88.13 6 10.66 95.57 6 3.32 83.40 6 20.31
Pravastatin lactone LQC 76.53 6 16.27 88.52 6 9.11 78.81 6 26.59
MQC 85.40 6 16.22 86.55 6 3.98 91.46 6 13.07
HQC 80.58 6 8.47 88.43 6 8.37 90.11 6 12.15
Pravastatin hydroxy acid LQC 78.56 6 7.80 77.32 6 5.06 77.83 6 11.90
MQC 83.08 6 13.27 81.71 6 26.71 78.73 6 5.33
HQC 81.95 6 15.63 88.73 6 31.67 88.48 6 5.36
Abbreviations: DMEM, Dulbecco’s modified eagle medium; HQC, high concentration quality control; LLOQ, lower limit of quantification; LQC,
low concentration quality control; MQC, medium concentration quality control; PBS, phosphate buffer saline.
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